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Abstract 
Keams-Sayre syndrome is the most commonly diagnosed mitochondrial cytopathy and produces evere neuromuscular symptoms. The 
most frequent cause is a mitochondrial DNA deletion that removes a 4977-base pair segment of DNA that includes several genes 
encoding for respiratory chain subunits. Treatment of AIDS patients with nucleoside analogs has been reported to cause mtDNA depletion 
and myopathies. Here, we report that azidothymidine, dideoxyguanosine, and dideoxycytidine cause a depletion of wild-type mtDNA 
while increasing the levels of deleted mitochondria DNA in Kearns-Sayre syndrome fibroblasts. The result of these effects is a large 
increase in the relative amounts of AmtDNA in comparison to wild type mtDNA. We found that Kearns-Sayre syndrome fibroblasts are a 
mixed population of cells with deleted mtDNA comprising from 0 to over 20% of the total mtDNA in individual cells. Treatment of 
cloned cell lines with dideoxycytidine did not result in increased levels of AmtDNA. The results suggest that nucleoside analogs may act 
to increase the average AmtDNA levels in a mixed population of cells by preferentially inhibiting the proliferation of cells with little or 
no AmtDNA. This raises the possibility that modulation of deleted mtDNA levels may occur by similar mechanisms in vivo, in response 
to the influence of exogenous agents. 
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1. Introduction 
Mitochondria play a vital role in the energy metabolism 
of eukaryotic cells by coupling the energy of substrate 
oxidation to ATP synthesis through oxidative phosphoryla- 
tion. Assembly of the mitochondrial respiratory chain re- 
sponsible for this process is dependent on the coordinated 
Abbreviations: AZT, 3'-azido-2',3'-dideoxythymidine; bp, base pairs; 
COX, cytochrome c oxidase activity; dCyd, 2'-deoxycytidine; ddCyd, 
2',3'-dideoxycytidine; ddGuo, 2'3'-dideoxyguanosine; mtDNA, mitochon- 
drial DNA; kb, kilobase; KSS, Kearns-Sayre Syndrome; AmtDNA, 
deleted mtDNA; PCR, polymerase chain reaction; PI, propidium iodide; 
SC-PCR, single cell polymerase chain reaction. 
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expression of two genomes, mitochondrial DNA (mtDNA) 
and nuclear DNA. In humans, mtDNA is an extremely 
compact genome that encodes 13 of the respiratory chain 
subunits. Damage to mtDNA leads to impaired energy 
metabolism and compromised cell function or viability [1 ]. 
Kearns-Sayre syndrome (KSS) is a neuromuscular dis- 
order usually associated with large scale rearrangements of 
mtDNA. The most frequent, the so-called 'common dele- 
tion', is a 4977-bp deletion that spans nucleotides 8470 to 
13447 and occurs in up to 50% of cases [2]. Patients with 
KSS may have progressive xternal ophthalmoplegia, pto- 
sis, muscle weakness, dementia, seizures, deafness, heart 
conduction defects, retinitis pigmentosa, lactic acidosis, 
and ataxia. Renal, hepatic, and endocrine disorders can 
also be manifested [2]. Cells of KSS patients are hetero- 
plasmic containing both wild type mtDNA and deleted 
mtDNA (AmtDNA). Although mtDNA deletions in differ- 
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ent patients may vary in length and position, each patient 
has only one type of AmtDNA. This suggests that dele- 
tions arise as a result of clonal expansion of a single 
molecular event in the germ line [2,3]. The levels of 
AmtDNA increase with age [4,5] and the increase is often 
associated with disease progression [4,5]. Consistent with 
these observations, mtDNA carrying mutations may have a 
selective replicative advantage over wild type mtDNA 
resulting in tissues with increased proportions of defective 
mtDNA [6]. While the mechanism(s) by which mtDNA 
deletions occur is unknown, one factor that may affect 
AmtDNA levels is ischemic stress. Chronically ischemic 
hearts showed 8 to 2200-fold increases in the levels of 
AmtDNA with the 4977-bp deletion, suggesting that im- 
pairment of oxidative phosphorylation may increase 
mtDNA damage [7]. The mechanism ay be by increasing 
a preexisting low level of AmtDNA present in the my- 
ocardium [7]. 
A variety of nucleoside analogs are used clinically as 
antiviral agents. Among these are 3'azido-2',3'-dide- 
oxythymidine (AZT, Zidovudine) and 2',3'-dideoxycyti- 
dine (ddCyd, Zalcitibine), that are currently used in the 
treatment of human immunodeficiency virus in patients 
with AIDS [8,9]. One of the dose-limiting side effects of 
AZT therapy is a reversible mitochondrial myopathy that 
has been associated with AZT-induced epletion of mtDNA 
[10-12]. AZT has been shown to inhibit replication of 
mtDNA in isolated mitochondria and in cells grown in the 
presence of AZT [13]. Severe mitochondrial toxicity aris- 
ing from depletion of mtDNA has also been noted with 
ddC [14,15]. A recent clinical trial with fialuridine (1-(2'- 
deoxy-2'-fluoro- 1-/3-D-arabinofuranosyl-5-iodo)uracil) in 
patients with hepatitis B had to be discontinued because of 
unacceptable mitochondrial toxicity [16,17]. 
To help understand the basis of mitochondrial toxicity 
of nucleoside analogs, we investigated the effects of sev- 
eral antiviral nucleosides on the levels of wild-type and 
deleted forms of mtDNA in cultured fibroblasts derived 
from KSS patients. We used a highly sensitive, quantita- 
tive, competitive polymerase chain reaction (PCR) assay to 
quantitate mtDNA and AmtDNA levels in cells treated 
with AZT, ddCyd and dideoxyguanosine, [18]. Both AZT 
and ddCyd are antiviral agents [8,9] and ddGuo has been 
tested as an antihepatitis agent [19]. We used concentra- 
tions of these agents that are associated with delayed 
toxicity and that are at or near plasma concentrations 
reached in clinical trials [20,21 ]. We found that the nucleo- 
side analogs caused a time- and dose-dependent depletion 
of mtDNA consistent with previous reports [10-15]. Sur- 
prisingly, the ratio of AmtDNA to mtDNA increased 
dramatically because of the combined effects of a decrease 
in wild-type mtDNA and a small increase in AmtDNA. 
Our results have important implications for the mechanism 
of inheritance of mtDNA, the natural history of mitochon- 
drial disease and for the use of antiviral agents in patients 
with preexisting mitochondrial disease. 
2. Materials and methods 
2.1. Reagents  
Restriction endonucleases were obtained from BRL 
(Gaithersburg, MD) or Boehringer Mannheim (Laval, Que- 
bec). c~-32p-Labeled CTP was from ICN Biomedicals 
Canada. Minimal essential medium (MEM) was from BRL. 
AZT was from Sigma (St. Louis, MO) and ddCyd and 
ddGuo were the kind gifts of Dr. D.L. Tyrrell (University 
of Alberta, Edmonton, Alberta). Oligonucleotides were 
synthesized with an Applied Biosystems, Model 392 
DNA/RNA Synthesizer. The human skin fibroblast cell 
line, TC558, was derived from a patient with Kearns-Sayre 
syndrome and was kindly provided by Dr. N. Kennaway 
(Oregon Health Sciences University, Portland, OR). The 
normal human fibroblast cell line, NF551 (#CCL-110), 
was obtained from the American Type Culture Collection 
(Rockville, MD). 
2.2. Cell culture 
Skin fibroblast cells were grown in MEM supplemented 
with 10% fetal bovine serum, 1% L-glutamine and 1% 
non-essential amino acids. Subconfluent cultures (about 
80%) were trypsinized with 1% trypsin and 0.5% EDTA. 
Cell pellets were washed once with fresh medium and cells 
(3 X 104) were placed in Coming 60-mm plates and grown 
at 37°C under 5% CO 2. After 18-24 h, cells were treated 
with fresh medium without added nucleoside or containing 
one of 10/~M AZT, 1 ~M ddCyd, 1 /zM ddGuo or 1 ~M 
dCyd. The culture media was changed every 3 days. Cell 
numbers were determined with a Coulter Counter-ZBI 
(Coulter Electronics, FL). Cell cycle compartment analysis 
was done by flow cytometry with propidium iodide (PI) 
staining. TC558 and NF551 cells were harvested at 70% 
confluence and the cells were resuspended at (1-2) × 10 6 
cells/ml. Cells were fixed in 70% ethanol at 4°C overnight 
and washed, pelleted and resuspended in 1 ml propidium 
iodide solution containing 0.1 mM PI, 1 mg/ml RNase in 
phosphate buffered saline. Flow cytometry was done using 
a Becton-Dickinson FACScan (Becton-Dickinson Canada). 
Cellular DNA content was measured by examining inten- 
sity of fluorescence at 488 nm. The relative numbers of 
cells in the G1, S and G2-M phases of the cell cycle were 
estimated using the software Cellfit Cell-Cycle Analysis 
Version 2.10.2. A minimum of 15000 cells of each type 
was examined. 
Cloned cell lines were isolated from the TC558 cell line 
by cell sorting. TC558 cells grown to about 80% conflu- 
ence were trypsinized, resuspended in fresh growth 
medium, and sorted with an Epics Elite Flowcytometer 
(Coulter, Canada Ltd.). Single cells were collected into 
individual wells of 96-well microtiter plates. After two 
weeks, cells from each clone were transferred to 25-cm 2
tissue culture flasks. Both TC558 and the clone, M530, 
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have been cultured continuously for over 15 passages. In 
some experiments cloned cell lines from TC558 were 
treated with 1 /xM ddC for 8 days. Cells of day 0, day 8 
and untreated cells from day 8 were then analyzed for 
mtDNA content as described below. In other experiments, 
single cells were isolated from TC558 by micromanipula- 
tion of individual cells from trypsinized cultures. The cells 
were then used for PCR analysis of mtDNA contents. 
2.3. Polymerase chain reaction 
The competitive PCR assay was used exactly as re- 
ported earlier [18]. Briefly, primers (MT-1, MT-3) flanking 
the 5-kb common deletion were used to produce a 280-bp 
product from AmtDNA. Primer MT-2 was within the 5-kb 
common deletion and with MT-1 produces a 394-bp prod- 
uct from normal mtDNA only. Competitive PCR was done 
by adding known amounts of plasmid containing the 280-bp 
and 394-bp products. The inserts of the plasmids were 
modified by site specific mutagenesis to contain a single 
additional restriction site. After production of the PCR 
products, the competitor could be distinguished from 
mtDNA by restriction enzyme digestion. Increasing 
amounts of competitor result in decreasing amounts of 
product from mtDNA thereby allowing quantification of 
mtDNA. To normalize for different numbers of cells in 
assay mixtures, we used a similar PCR assay for a single 
copy nuclear gene. We have earlier described this PCR 
assay for mtDNA and AmtDNA that gives highly repro- 
ducible and accurate results of mtDNA levels [18]. Results 
are shown as a ratio of moles AmtDNA/mol mtDNA. 
2.4. Other methods 
Measurements of cytochrome c oxidase activity were as 
reported [22]. Briefly, subconfluent cultures were har- 
vested by trypsinization, washed twice with buffered saline, 
and lysed in saline by freeze-thawing three times. The cell 
lysate protein concentration was determined with the DC 
Protein Assay (Bio-Rad Laboratories, Mississaugua, Ont.). 
L-Lactic acid determinations were done as described by the 
kit supplier (Boehringer Mannheim, Laval, Quebec) with 
3-day culture media heated to 80°C for 15 min. 
2.5. Statistical ec, aluation 
Results are displayed as mean + standard eviation (SD) 
of the mean. Significance was evaluated using a t-test. 
P < 0.05 was the minimum significant difference between 
the groups being compared. 
3. Results 
Initial experiments tested the effects of AZT, ddCyd, 
and ddGuo on growth of human Kearns-Sayre syndrome 
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Fig. 1. Flow cytometry plots of cell cycle distribution. Plots of DNA 
content versus cell number are shown for TC558 fibroblasts (Panel A) 
and NF551 fibroblasts (Panel B). Cellular DNA content was measured by 
examining fluorescence at 488 nm after propidium iodide staining as 
described in Section 2. The relative numbers of cells in the Gj, S and 
G2-M phases of the cell cycle were estimated using the software Cellfit 
Cell-Cycle Analysis Version 2.10.2. 
TC558 fibroblasts. Our purpose was to examine which 
concentrations would be useful for experiments on mtDNA 
levels. AZT from 1-10 /xM and ddGuo and ddCyd from 
0.1-1 /xM had little or no effect on cell growth (not 
shown). A higher concentration f AZT (20 /xM) caused a 
33% reduction in cell numbers over an 8-day period and 
was not used for further study. Treatment with these 
compounds did not affect cell morphology (not shown). 
We compared the growth rates and cell cycle distribu- 
tions of TC558 and normal type (NF551) fibroblasts. The 
mean doubling times of NF551 and TC558 cultures were 
21.6 and 33.6 h, respectively. Thus, the growth rate of 
TC558 is reduced in comparison to that of NF551. To 
examine this difference in more detail, we compared the 
cell cycle distribution of actively proliferating NF551 and 
TC558 cells by flow cytometry. The results (Fig. 1) showed 
that there was a large decrease (60-70%) in the relative 
numbers of TC558 cells in S and G2-M phases in compari- 
son to NF551 cells. The percentage of cells in the G 1, S 
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Fig. 2. Determination f AmtDNA content of fibroblast cells treated with 
ddCyd. Normal human skin fibroblast cells (NF551) were grown with 1 
/xM ddCyd for 2, 4 and 8 days. PCR reactions used one /~1 of cell lysate 
and primers for both mtDNA and AmtDNA. Lane 1; TC558 cells, 
(contain AmtDNA). Lanes 2, 3 and 4 are NF551 cells (contain normal 
mtDNA) treated with ddCyd for 2, 4 and 8 days, respectively. The 394-bp 
band contains the PCR fragment expected for normal mtDNA, and the 
280-bp band contains the PCR product of AmtDNA. 
and Gz-M phases were 62.5, 24.9 and 12.7 for NF551 and 
87.9, 7.9 and 4.1 for TC558 cells, respectively. 
We next examined whether treatment with ddCyd could 
induce formation of the common deletion in cells that 
lacked AmtDNA. Normal human fibroblasts, (NF551), 
were treated with 1 /xM ddCyd for up to 8 days. PCR [18] 
was used to assay for the presence of wild-type and 
AmtDNAs in treated and untreated cells (Fig. 2). We could 
not detect he 280-bp PCR product indicative of the 4977- 
bp deletion in ddCyd-treated cells. We also could not 
detect AmtDNA in ddCyd-treated cells (not shown) when 
we used a more precise quantitative PCR assay described 
previously [18], that can detect as few as 0.2 copies of 
AmtDNA DNA per cell. Therefore, ddCyd treatment did 
not cause the formation of measurable amounts of 
ZlmtDNA. 
We examined whether the nucleoside analogs differen- 
tially affected the amounts of mtDNA and AmtDNA in 
TC558 cells. The defect in TC558 cells is a 5-kb deletion 
of the mitochondrial genome usually referred to as the 
common deletion [5]. We treated cells for 8 days in 
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Fig. 3. Mitochondrial DNA content of nucleoside-treated TC558 fibrob- 
lasts. Cells were grown without additions (controls) or in medium con- 
taining various nucleosides (10 /zM, AZT, 1 /xM ddCyd, l /xM ddGuo, 
1 /xM dCyd) for 8 days. Cell lysates were prepared for the quantitative 
PCR determination of normal mtDNA (A) or AmtDNA (B). Each 
mtDNA determination is the mean 5: S.E. at least 3 independent experi- 
ments. 
medium containing 1 /zM dCyd, 10 /zM AZT, 1 /xM 
ddCyd, or 1 /~M ddGuo. Untreated cells contained be- 
tween 5000 and 6000 copies of wild-type mtDNA per cell 
and this number did not change over the time of the 
experiment (Fig. 3A) [18]. Treatment with dCyd (1 /xM) 
did not affect he levels of mtDNA (Fig. 3A). In contrast, 8
days of treatment with AZT, ddGuo, or ddCyd resulted in 
significant depletion of wild-type mtDNA with levels of 
mtDNA that were 86%, 50%, and 31% of control values 
(Fig. 3A). 
Surprisingly, we found that AmtDNA levels were not 
decreased but rather increased slightly (P  < 0.05) in TC558 
cells treated with AZT, ddCyd, or ddGuo (Fig. 3b). Un- 
Effect of nucleosides on mitochondrial DNA content and ratio of mtDNA to AmtDNA 
Treatment Time (days) mtDNA AmtDNA Ratio × 10- 2 
Control 8 5612 + 293 96 + 5 1.71 5:0.11 
1 /xM dCyd 8 5188 + 664 85 + 11 1.64 5:0.24 
10/zM AZT 8 4818 5:515 ~ 124 5:_ 8 b 2.57 5:0.36 b 
10 /zM AZT 16 3379 + 411 ~ 119 5:18 h 3.52 5:0.40 ~ 
1 /~M ddGuo 4 3748 5:162 b 136 ± 14 b 3.63 5:0.75 b 
l /xM ddGuo 8 2801 5:327 b 122 5:19 b 4.36 5:0.49 b 
1 /zM ddCyd 4 3879 + 214 b 180 5:16 h 4.64 5:0.48 b 
1 /~M ddCyd 8 1759 + 283 b 126 5:15 b 7.16 5:0.73 b 
Cells were treated with nucleoside analogs for 4, 8, or 16 days as indicated. Cell lysates were prepared for quantitative PCR and the amounts of mutant and 
wild-type mtDNA/cell were determined. Untreated cells (control) had a constant ratio; the value given is the average of values obtained at 2, 4 and 8 days 
* P<0.05,  bp<0.01 .  
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Fig. 6. Distribution of AmtDNA content in single TC558 cells. Seventy- 
two single cells were isolated by micromanipulation a d subjected to 
SC-PCR to determine the proportion of AmtDNA. Results are presented 
as a percent of the total (72) TC558 cells studied. 
Fig, 4. Mitochondrial DNA PCR products of control or ddCyd treated 
TC558 cells. Cells were grown without additions (controls, lane 1 and 2) 
or in medium containing 1 /xM ddCyd (lane 3 and 4). After 12 (lanes 1 
and 3) or 14 (lanes 2 and 4) days cells were harvested and DNA was 
amplified by PCR using the primers MT1, MT2 and MT3. 
treated TC558 cells had about 100 copies of AmtDNA per 
cell. While treatment with dCyd did not significantly alter 
the level of AmtDNA, treatment with AZT, ddCyd, or 
ddGuo increased AmtDNA levels up to 130% of levels in 
untreated cells. Table 1 shows the time dependence of 
these effects as well as the effects on the ratios of AmtDNA 
to wild-type mtDNA. The depletion of normal mtDNA 
became more severe as treatments were prolonged from 4 
to 8 days for ddCyd and ddGuo, or from 8 to 16 days for 
AZT. The effects of extended treatments on AmtDNA 
levels were variable depending on the time and compound 
used. The maximum increase in the AmtDNA to mtDNA 
ratio was 418% of control values with treatment with 1 
/xM ddCyd for 8 days. 
To further document the effect of nucleoside analogs on 
the levels of mtDNA and AmtDNA, we treated TC558 
cells with 1 /~M ddCyd for up to 14 days. Control cells 
were untreated but originated from the same flask of cells 
and were handled identically. Samples were collected after 
12 and 14 days of treatment and fragments of mtDNA or 
AmtDNA were amplified using PCR with the primers 
MT-1, MT-2 and MT-3. The results are illustrated in Fig. 
4. In both the 12- and 14-day controls (lanes 1 and 2) the 
levels of mtDNA remained high and the levels of AmtDNA 
remained low. In contrast, the level of mtDNA declined 
sharply after 12 and 14 days of treatment with ddCyd. 
However, the amount of AmtDNA did not decrease and 
showed a slight increase, particularly after 14 days of 
treatment (lane 4). The ratios of mtDNA to AmtDNA were 
estimated from the amounts of the 2 products. The propor- 
tions of AmtDNA to mtDNA increased 2.8- and 3.9-fold 
after 12 and 14 days, respectively. 
We characterized the heterogeneity of the TC558 cell 
line for its AmtDNA and mtDNA content. Single cells 
were isolated by micromanipulation and subjected to a 
SC-PCR assay with the primers MT-1 and MT-3 which 
amplify the 280 bp product of AmtDNA. Results are 
shown in Fig. 5 for 20 individual cells. The TC558 cell 
line was heterogeneous in that some cells did not contain 
any detectable AmtDNA (lanes 9,10,13-15,19) while in 
others, the proportions of AmtDNA varied considerably. 
One cell had a 20 to 50-bp larger deletion (lane 3), that 
was not studied further. 
To determine the relative proportions of AmtDNA and 
mtDNA in individual TC558 cells, we used SC-PCR with 
the three primers, MT-1, MT-2, and MT-3. The results are 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
DNA 
Fig. 5. Comparison of AmtDNA levels in individual TC558 cells. Individual TC558 cells were subjected to SC-PCR using the primers MT-1 and MT-3 to 
amplify a 280-bp fragment originating from deletion-containing mtDNA. The amplification products were electrophoresed as described in Section 2. The 
arrow indicates the location of the diagnostic band. 
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shown in Fig. 6. We determined the relative amounts of 
the 394-bp and 280-bp products, that reflected wild-type 
mtDNA levels and AmtDNA levels, respectively. Of 72 
cells so tested, 15 (20.8%) had no detectable AmtDNA. 
The highest content of AmtDNA found in this series of 
tests comprised 18.5% of total mtDNA. These results 
represent a distribution around the mean population value 
of 2% that we reported earlier [18]. 
To examine the growth characteristics of the population 
of TC558 cells in more detail, individual cells were sorted 
by flow cytometry and collected and propagated in individ- 
ual wells of four 96-well microtiter plates. From these 
cells, 121 clones were obtained and 46 grew well enough 
to analyze their mtDNA contents by PCR. Again, the 
heterogeneous nature of the TC558 cell line was evident. 
In this experiment 27 (59%) of the clones were free of 
AmtDNA. The relative amount of homoplasmic wild type 
cells was 3-fold greater than that found by analysis of cells 
isolated via micromanipulation. This enrichment demon- 
strates that homoplasmic wild-type cells have better viabil- 
ity than heteroplasmic cells under our culture conditions. 
Thus, the cell line TC558 contains a variety of different 
cell types with varying ability to propagate. 
Among the 19 heteroplasmic clones that we isolated, 
there were large variations in the proportions of AmtDNA. 
The precise ratios of AmtDNA in three clones with greatly 
different proportions of mutated mtDNA were determined 
by quantitative competitive PCR. Clones M530, M528, 
and M529 contained 22.9%, 0.56%, and 0.003% AmtDNA, 
respectively (Table 2). Another clone (M538) contained 
60.5% AmtDNA (not shown). Examination by light mi- 
croscopy revealed no obvious differences in morphology 
between clones. 
We examined the doubling times of TC558 and several 
of the clones with varying degrees of heteroplasmy (Table 
2). There was no correlation between doubling time and 
the amount of AmtDNA. We also examined the relation- 
ship between AmtDNA and cytochrome C oxidase activity 
(COX) and lactic acid production. Surprisingly, there was 
not a strong correlation between either parameter and 
AmtDNA, although cells with AmtDNA generally had 
higher lactic acid production than cells without AmtDNA. 
However we had isolated 384 cells by flow cytometry of 
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Fig. 7. Stability of AmtDNA levels during long-term culture. TC558 and 
M530 cells were subcultured every 4-5 days into fresh medium. Cell 
lysates were made after every passage and used for quantitative competi- 
tive PCR analysis of wild-type and AmtDNA levels. TC558, ( r, ); M530, 
(+).  Each point is the average of three determinations, mtDNA contents 
were determined as described in the text. 
which only 121 clones survived. Of these only 46 grew 
well enough to examine. Thus, the surviving cells of these 
experiments may represent a subset of the original popula- 
tion that is selected for their ability to grow in culture. 
We also examined the stability of the heteroplasmic 
condition in TC558 and M530 cells during extended cul- 
ture (Fig. 7). AmtDNA proportions in TC558 cultures 
dropped from 1.7% to 0.56% after 7 passages and further 
to 0.26% after 18 passages (not shown). No changes in the 
wild-type mtDNA levels were detected. When M530 cells 
were cultured under identical conditions, the AmtDNA 
levels remained relatively unchanged for up to 12 passages 
after which cell viability decreased rapidly (Fig. 7). Thus it 
is clear that some cells of the TC558 population can retain 
the AmtDNA better than the whole population. The differ- 
ence may be due to the presence of homoplasmic wild-type 
cells in the TC558 culture that grow more rapidly in 
culture than AmtDNA containing cells. In M530, a cloned 
cell line, all cells contained AmtDNA. SC-PCR analysis of 
21 cells of M530 confirmed that all M530 cells contained 
AmtDNA although the amount varied from over 35% to 
below 20%. 
We examined the effect of ddCyd on AmtDNA content 
Table 2 
Characterization of clonal cell lines and TC558 cells 
Ceil % of AmtDNA a Doubling time (h) COX b ( /xM'  min- I . mg- I) Lactic acid c (mg/cell x 104) 
TC558 1.71 33.6 1.53 -t-_ 0.53 13.3 +_ 2.09 
M528 0.56 27.9 2.21 5:0.49 13.4 5:0.67 
M529 0.003 45.7 2.82 -t-_ 0.89 18.0 _+ 0.46 
M530 22.85 31.8 1.08 + 0.27 15.7 5:0.85 
M531 0 17.3 2.26 ___ 0.35 11.7 + 0.35 
a The ratio indicates the percent AmtDNA of total mtDNA. 
b Cells used in COX assay were in passage 4 (M528, M531), passage 5 (TC558) and passage 6 (M529, M530). 
c The medium used in lactic acid assay was from 3-day-old cultures. 
Results represent the mean + S.E. of at least three experiments. 
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Fig. 8. MtDNA contents in cloned cell lines treated with l /zM ddCyd. 
Cell lysates were prepared for PCR determination f normal mtDNA and 
AmtDNA ratios. The levels were determined in the cloned cell lines 
M538 and C529 which were either untreated (C), treated with 1 /xM 
ddCyd for 8 days (+ ddC), or treated with vehicle alone for 8 days 
(-ddC). The ratios were compared to those of control cells prior to 
treatment. Absolute ratios were 0.605 and 0.059 for M538 and C529, 
respectively. Each mtDNA determination represents he mean_+ S.E. of at 
least 3 independent experiments. Where not shown S.E. were too small to 
be displayed. 
of two clonal cell lines: M538 which had a high content of 
AmtDNA (60.5%) and C529 which had 1/10 that level 
(5.9%). The cells were treated with ddCyd for 8 days, and 
the AmtDNA content was determined before treatment, 
after 8 days of 1 ~M ddCyd or no treatment (Fig. 8). In 
both cases, treatment with ddCyd resulted in no significant 
increase in the relative amounts of AmtDNA. A third cell 
line with less than 1% AmtDNA also showed no signifi- 
cant increase in AmtDNA levels upon treatment (not 
shown). 
4. Discussion 
The purpose of our study was to examine the effect of 
antiviral nucleoside analogs on the levels of wild-type and 
deleted forms of mtDNA in cultured fibroblasts derived 
from KSS patients. Initial experiments compared the 
growth rates and cell cycle distribution of TC558 (KSS 
fibroblasts) and normal type (NF551) fibroblasts. The re- 
suits (Fig. 1) showed that were consistent differences 
between these cell types. While a causal relationship has 
not been established, these results suggest that the presence 
of a small amount of AmtDNA may have effects on the 
growth and cell cycle distribution of human fibroblast 
cells. It should be noted that NF551 and TC558 have 
different origins and are not isogenic cell lines. Further 
experiments will be necessary to confirm that the differ- 
ences observed in growth rate were due to the presence of 
AmtDNA. 
We examined the effect of nucleosides on the levels of 
AmtDNA cells treated with nucleoside analogs. For quanti- 
tative analysis we used a competitive PCR [18] assay 
which we have developed earlier. This PCR assay is based 
on competition with a template that is identical to target 
DNA with the exception of the introduction of a restriction 
site. PCR, although highly sensitive, can be inhibited by 
the presence of inhibitors in samples. Because of the 
coamplification of both target and competitor, changes in 
amplification efficiency will not affect the results obtained 
[ 18]. In addition we have shown earlier that competitor and 
target DNA amplify with equal efficiency [18] validating 
the utility of the assay. 
We initially determined whether ddCyd can itself, in- 
duce formation of the AmtDNA. The results (Fig. 2) 
showed that ddCyd did not induce formation of AmtDNA 
mutation. However, treatment of heteroplasmic KSS fi- 
broblast with AZT (10 /~M), ddGuo (1 /xM), or ddCyd (1 
/zM) resulted in significant reductions of wild-type mtDNA 
with levels of mtDNA that were 86%, 50%, and 31% of 
control values (Fig. 3A). AZT and ddCyd can cause 
mitochondrial myopathies both in vitro and in vivo [10- 
15,23]. In addition, treatment of cells in culture with 
ddCyd or other nucleoside analogs has been shown to lead 
to a loss of mtDNA [14,15,23]. Although one study [24] 
showed no effect of AZT on mtDNA content of cultured 
human muscle cells, mtDNA depletion has been observed 
in other cell types including human fibroblasts, human 
lymphoblastoid CEM cells [15], human leukemic Molt-4F 
cells [14] and human lymphoblasts [23]. This difference 
may be due to the relatively slower rate of muscle cell 
growth in comparison to that of other cell types. In our 
study we found similar results to that observed earlier 
[14,15,23]. 
The most surprising results of the study were that 
treatment with AZT, ddCyd, or ddGuo resulted in in- 
creased AmtDNA levels in TC558 cells (Fig. 3b). The 
effects were time and dose dependent. Combined with the 
loss of mtDNA, the increased AmtDNA resulted in rela- 
tively large increases in the ratio of AmtDNA to mtDNA 
(Table 1). These effects on mtDNA levels may be impor- 
tant to cell function. It has been suggested that the ratio of 
AmtDNA to mtDNA may be the critical parameter influ- 
encing mitochondrial function [25]. In untreated cells the 
ratio was 0.017. This ratio did not change during the 
experiments for untreated cells and was unaffected by 
treatment with 1 /zM dCyd. In contrast, treatment with 
AZT, ddGuo, and ddCyd resulted in ratios that were 
0.0352, 0.0436 and 0.0716, respectively. It should be noted 
that the potency of ddCyd was much greater than that of 
AZT or ddGuo (Table 1). These compounds reduce mtDNA 
content of lymphoblastoid cells with the same order of 
potency [15]. Because of the similarity in the order of 
potency for effects on mtDNA depletion [15], and the 
effects on ratios of AmtDNA to mtDNA, it may be that 
the mechanisms of these two effects are related. In addi- 
tion, though the changes in the absolute amounts of 
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AmtDNA were small, even the presence of a fraction of 
0.017 AmtDNA in the mixed population of cells (TC558) 
may cause small effects on the growth and cell cycle 
distribution (Fig. 1). These effects on growth with different 
AmtDNA content, varied greatly between individual cloned 
cell lines (Table 2). We showed that over long periods of 
time the elevation of the ratio of AmtDNA to mtDNA was 
quite pronounced and that the proportion of AmtDNA 
increased up to 3.9-fold after 14 days of treatment (Fig. 4). 
A simple explanation for the decrease in mtDNA and 
increase in AmtDNA may relate to a characteristic of the 
TC558 cell line. If this cell line is a mixed population of 
cells with different AmtDNA content, nucleoside analogs 
may preferentially affect cells with a low AmtDNA con- 
tent. We showed that the TC558 cells are a very heteroge- 
neous mix of cells with the amount of AmtDNA varying 
from none to over 18.5% (Figs. 5 and 6). A greater 
inhibition of the growth of cells with low or no AmtDNA 
would result in an increase in the AmtDNA content. To 
test this hypothesis, we examined the effect of ddCyd on 
AmtDNA content of two clonal cell lines: M538 which 
had a high content of AmtDNA (60.5%) and C529 which 
had 1/10 that level (5.9%) (Fig. 8). In these cases, treat- 
ment with ddCyd resulted in no significant increase in the 
relative amounts of AmtDNA. These results contrasted 
sharply with those found upon treatment of TC558 cells 
(Table 1) where with the same treatment increased the 
levels of AmtDNA over 4-fold. Thus nucleosides may act 
to increase AmtDNA by affecting the rate of growth of the 
various cell types within a mixed population. It was clear 
that with clonal cell lines, ddCyd did not act to increase 
the AmtDNA/mtDNA ratio. 
Our results showed a heterogeneous distribution of 
AmtDNA in the population of TC558 cells. Comparison of 
the AmtDNA distribution of cells analyzed by SC-PCR 
and cells grown in culture indicated that cells with varying 
amount of AmtDNA could survive and grow in culture 
with different efficiencies. Cells with homoplasmic wild 
type mtDNA survived much better in culture than those 
that were heteroplasmic; the proportion of homoplasmic 
cells was enriched over 3-fold in comparison to TC558 
cells. Given this observation it might be expected that 
TC558 cells and human tissues would rapidly lose the 
mutated mtDNA. Because the opposite often occurs [26], 
other factors must be involved. One of these may be the 
differences in the cell types within the population. During 
13 passages, M530 (Fig. 7) did not progressively lose 
AmtDNA suggesting that some cell types can vary in their 
ability to gain or lose AmtDNA. We suggest that AZT and 
non-azidylated analogs differentially affect the prolifera- 
tion of cells within a mixed population. Our results with 
the clonal cell lines (Fig. 8), support this concept. If 
homoplasmic wild type cells, or cells with low amounts of 
AmtDNA are selected against, the remaining population 
would have a higher proportion of AmtDNA. This in- 
crease, combined with the depletion of mtDNA [15], can 
account for our observation of increased ratios of AmtDNA 
in TC558 cells (Table 1). 
The mechanism by which AZT and non-azidylated 
analogs affected the growth or survival of some cell types 
is not yet known but may be related to mitochondrial 
energy generation. A common factor that determines the 
intracellular distribution of AZT and non-azidylated 
analogs could explain how the two types of analogs have 
similar effects on mtDNA ratios. Mitochondria containing 
wild-type mtDNA would have a fully functional respira- 
tory chain and a normal electrochemical proton gradient 
that may be important for the uptake and or metabolism of 
the analogs. Conversely, mitochondria containing 
AmtDNA might be deficient in transporting or metaboliz- 
ing the analogs due to impaired respiratory activity. The 
reduced amounts of nucleotide analogs in mitochondria 
with AmtDNA could explain why AZT, ddCyd and ddGuo 
do not cause a depletion of AmtDNA in cells with this 
mutation. It should be recognized that this proposed mech- 
anism awaits experimental verification by future experi- 
mentation. Further studies are necessary to test if mito- 
chondria with AmtDNA have significant differences in 
membrane potential. 
The number and incidence of mtDNA deletions has 
been shown to accumulate to significant levels with age in 
healthy individuals [1,4,5]. MtDNA dysfunction is also 
implicated in neurodegenerative disorders [ 1 ]. Our observa- 
tion that exogenous agents can quickly increase the ratio of 
AmtDNA to mtDNA raises the possibility that in normal 
humans treated with such agents, small sub-clinical clones 
of deleted mtDNA such as seen in aging [27], might be 
amplified to pathological levels. The increases in the ratio 
of AmtDNA to mtDNA that we observed may be more 
important to mitochondrial function than the actual 
AmtDNA numbers [25]. This mechanism would only apply 
to dividing tissues and could not function in post-mitotic 
tissues where accumulation of mtDNA mutations occurs 
with age [28]. It is interesting to note that in one study 
AZT did not affect mtDNA levels in cultured human 
muscle cells [24] while in other dividing cell types, signifi- 
cant effects were reported [14,15,23]. It will be critical to 
determine whether the effects we observed on AmtDNA 
occur in vivo in a number of cell types and whether they 
might occur with other types of mutations in the mitochon- 
drial genome and with other nucleoside analogs. 
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